Latest market price
18.55
+0.09+0.51%
VREXQT80Varex Imaging Corporation·NASDAQ
18.55+0.51%
TA
Loading chart...
Screen all →
Snapshot
Index—P/E35.50EPS (ttm)0.52Insider Own2.52%Shs Outstand42.46MPerf Week0.27%
Market Cap783.87MForward P/E13.19EPS next Y1.40Insider Trans-12.89%Shs Float41.37MPerf Month0.00%
Enterprise Value1.05BPEG1.09EPS next Q0.33Short Float3.94%Perf Quarter49.23%
Income22.00MP/S0.91EPS this Y27.38%Short Ratio1.92Perf Half Y59.00%
Sales866.00MP/B1.53EPS next Y30.84%ROA2.01%Short Interest1.63MPerf YTD58.45%
Book/sh12.03P/C7.92EPS next 5Y32.69%ROE4.60%52W High18.63 -0.40%Perf Year55.78%
Cash/sh2.33P/FCF—EPS past 3/5Y—ROIC6.41%52W Low9.09 104.13%Perf 3Y6.15%
Dividend Est.—EV/EBITDA11.09Sales past 3/5Y-0.55% 2.74%Gross Margin34.32%Volatility0.30% 0.28%Perf 5Y-31.76%
Dividend TTM—EV/Sales1.22EPS Y/Y TTM—Oper. Margin8.35%ATR (14)0.06Perf 10Y—
Dividend Ex-Date—Quick Ratio1.53Sales Y/Y TTM5.35%Profit Margin2.55%RSI (14)62.51Recom2.71
Dividend Gr. 3/5Y—Current Ratio3.38EPS Q/Q72.22%SMA200.12%Beta1.03Target Price14.50
Payout0.00%Debt/Eq0.72Sales Q/Q3.94%SMA50-0.02%Rel Volume0.99Prev Close18.46
Employees2,500LT Debt/Eq0.69EarningsNov 17SMA20035.51%Avg Volume912.19KPrice18.55
IPO DateJan 23, 2017Option/ShortYes / YesEPS/Sales Surpr.47.58% -2.32%Net Debt/EBITDA2.84Volume903,524Change0.51%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-17-26DowngradeCJS SecuritiesOutperform → Market Perform
Aug-11-26DowngradeOppenheimerOutperform → Perform
Aug-10-26DowngradeSidoti & Co.Buy → Neutral
Feb-02-26ReiteratedJefferiesHold$17 → $15
May-28-24ReiteratedJefferiesHold$17
Feb-05-21UpgradeOppenheimerPerform → Outperform
Aug-13-20DowngradeOppenheimerOutperform → Perform
May-13-20DowngradeJP MorganOverweight → Neutral
Mar-25-20UpgradeJP MorganNeutral → Overweight
Feb-12-20DowngradeJefferiesBuy → Hold
Latest News· Times ET
Oct-28-26
Oct-27-26
Oct-21-26
Oct-20-26
Oct-19-26
Sep-24-26
Sep-16-26
Sep-12-26
Sep-05-26
Sep-02-26
Aug-28-26
Aug-24-26
Aug-23-26
Aug-15-26
Company

Varex Imaging Corporation (VREX) specializes in the development and production of X-ray imaging components. Its operations are divided into two primary divisions: Medical and Industrial. Within the Medical segment, Varex provides a comprehensive range of X-ray imaging components. These include essential hardware like X-ray tubes, digital detectors, and high-voltage connectors, alongside sophisticated software solutions for image processing, 3D reconstruction, and computer-aided diagnostics. The segment also supplies critical ancillary devices such as collimators, generators, and automatic exposure control mechanisms. These medical products serve a wide spectrum of applications, from general diagnostic imaging like radiography and fluoroscopy, to specialized areas such as mammography, computed tomography (CT), cardiac procedures, dental imaging, and surgical applications. They are also vital for radiation therapy, oncology, and advanced computer-aided detection systems. The Industrial segment focuses on providing X-ray technology for security and industrial inspection. Its offerings include Linatron X-ray accelerators, X-ray tubes, digital detectors, and high-voltage connectors. These components are crucial for diverse applications such as airport security scanning, cargo screening at border crossings, and nondestructive testing across various industries. Varex distributes its products through multiple channels, including direct sales to end-users, partnerships with imaging system Original Equipment Manufacturers (OEMs), independent service providers, and a network of distributors. With a significant global footprint, the company maintains operations across North America, South America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Established in 2016, Varex Imaging Corporation is headquartered in Salt Lake City, Utah.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
10/3/2025
FY 2024
9/27/2024
FY 2023
9/29/2023
FY 2022
9/30/2022
FY 2021
10/1/2021
FY 2020
10/2/2020
FY 2019
9/30/2019
FY 2018
9/30/2018
Total Revenue866845811893—————
Cost of Goods Sold Incl. D&A568554554603—————
Gross Profit298291257290—————
Selling, General and Administrative Excl. Other134133138128—————
Research and Development91918785—————
Other Operating Expense-19400—————
Operating Income72-283277—————
Interest Expense39363129—————
Unusual Expense
—————————
Non-Operating Income (Expense)-644-16—————
Net Income Before Taxes28-59531—————
Income Taxes51152-17—————
Consolidated Net Income22-70-4847—————
Net Income From Continuing Operations22-70-4748—————
Net Income22-70-4847—————
EPS (Recurring)0.52-1.70-1.171.20—————
EPS (Basic, Before Extraordinaries)0.52-1.70-1.171.20—————
EPS (Diluted)0.52-1.70-1.170.96—————
EBITDA9546395—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio35.68——19.57—————
Price To Sales Ratio0.900.580.600.84—————
Gross Margin34.4134.4431.6932.47—————
Operating Margin8.31-3.313.958.62—————
Net Margin2.54-8.28-5.925.26—————
Shares Outstanding42414140—————
Market Capitalization779490489752—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$19.97$16.96$13.95$10.94$7.93● Close Price0.00M0.64M1.28M1.91M2.55MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kunkel Jay K.DirectorSep 14 '26Sale18.488,121150,07615,329Sep 15
Maheshwari ShubhamChief Financial OfficerSep 11 '26Sale18.46130,0002,400,060139,972Sep 15
Maheshwari ShubhamChief Financial OfficerSep 11 '26Option Exercise13.61160,9442,190,448269,972Sep 15
Aranki Karen LChief Human Resources OfficerAug 14 '26Option Exercise0.003,97408,893Aug 18
Kunkel Jay K.DirectorMar 20 '26Sale11.144,51050,24123,450Mar 23
Kunkel Jay K.DirectorFeb 09 '26Option Exercise0.008,483027,960Feb 10
Rosebrough Walter M JrDirectorFeb 09 '26Option Exercise0.0010,339052,654Feb 09
Chertoff Jocelyn DDirectorFeb 09 '26Option Exercise0.008,483042,194Feb 09
GUERTIN TIMOTHY EDirectorFeb 09 '26Option Exercise0.008,483026,777Feb 09
Bardwell KathleenDirectorFeb 09 '26Option Exercise0.008,483012,102Feb 09
TSINGOS CHRISTINE ADirectorFeb 09 '26Option Exercise0.008,483042,655Feb 09
Jonaitis Mark S.SVP and GM, X-Ray SourcesDec 10 '25Option Exercise0.0012,599082,867Dec 12
Hartmann AndrewSVP and GM, DetectorsDec 10 '25Option Exercise0.0012,599039,818Dec 12
SANYAL SUNNYPresident and CEODec 10 '25Option Exercise0.0074,2650264,458Dec 12
Aranki Karen LChief Human Resources OfficerDec 10 '25Option Exercise0.006,66506,842Dec 12
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.